- Clinical Trials
- November 2024
- 60 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Report
- June 2024
- 200 Pages
Global
From €7621EUR$7,950USD£6,368GBP
- Report
- March 2025
- 219 Pages
Global
From €4789EUR$4,995USD£4,001GBP
- Report
- January 2024
- 150 Pages
Global
From €4650EUR$4,850USD£3,885GBP
- Report
- January 2022
- 60 Pages
Global
From €3787EUR$3,950USD£3,164GBP
- Report
- January 2022
- 60 Pages
Global
From €3787EUR$3,950USD£3,164GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- August 2022
- 110 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- May 2022
- 37 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- May 2022
- 36 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- May 2022
- 39 Pages
Global
From €1917EUR$2,000USD£1,602GBP

Keratitis is an inflammation of the cornea, the clear outer layer of the eye. It is caused by a variety of infectious agents, including bacteria, viruses, fungi, and parasites. Infectious Diseases Drugs are used to treat keratitis, and the Keratitis Drug market is a subset of the larger Infectious Diseases Drugs market.
Keratitis Drugs are typically administered topically, either as eye drops or ointments. They are designed to reduce inflammation, reduce pain, and eliminate the infectious agent. Commonly used drugs include antibiotics, antivirals, antifungals, and antiparasitics.
The Keratitis Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Allergan, Bausch + Lomb, Merck, Pfizer, and Novartis. Show Less Read more